HAVN Life Sciences Inc.
HAVN
CNSX
| 01/31/2023 | 10/31/2022 | 07/31/2022 | 04/30/2022 | 01/31/2022 | |
|---|---|---|---|---|---|
| Net Income | 70.30% | 103.99% | -25.48% | -2.72% | 83.12% |
| Total Depreciation and Amortization | -99.90% | -114.99% | -66.73% | -93.98% | -88.44% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -72.68% | -126.03% | 443.80% | 102.70% | -93.08% |
| Change in Net Operating Assets | 2,218.85% | 182.66% | 179.71% | 77.10% | 165.66% |
| Cash from Operations | 118.80% | 78.72% | 66.01% | 66.32% | 58.95% |
| Capital Expenditure | -- | -- | -- | 100.00% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | 100.00% | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | 100.00% | 100.00% |
| Cash from Investing | -- | -- | -- | 121.99% | -211.63% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | 200.00% | 0.00% | 0.00% | -- |
| Issuance of Common Stock | -- | -- | -- | 301.69% | -100.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -715.89% | 5,984.48% | -54.14% | 248.86% | -100.22% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 100.34% | 97.15% | 75.11% | 105.32% | -113.25% |